Add Company
Join Now

Avenue Therapeutics Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Avenue Therapeutics's estimated annual revenue is currently $2M per year.(i)
  • Avenue Therapeutics's estimated revenue per employee is $201,500

Employee Data

  • Avenue Therapeutics has 10 Employees.(i)
  • Avenue Therapeutics grew their employee count by -9% last year.

Avenue Therapeutics's People

NameTitleEmail/Phone
1
CEO and Member Board DirectorsReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
VP Clinical Operations and Program ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M30%N/AN/A
#2
N/A2043%N/AN/A
#3
$6.7M33-6%N/AN/A
#4
$34.4M222-1%N/AN/A
#5
$5.2M670%$10MN/A
#6
$2M130%N/AN/A
#7
$7.5M370%$51.6MN/A
#8
$0.3M1-50%N/AN/A
#9
$4.3M21-16%$3.3MN/A
#10
$3.6M205%N/AN/A
Add Company

What Is Avenue Therapeutics?

Avenue Therapeutics, Inc. (NASDAQ: ATXI), a Fortress Biotech (NASDAQ: FBIO) Company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol for the management of moderate to moderately severe postoperative pain. IV tramadol may fill a gap in the acute pain market between IV acetaminophen/NSAIDS and IV conventional narcotics. Avenue is currently evaluating IV tramadol in a pivotal Phase 3 program for the management of postoperative pain.

keywords:N/A

N/A

Total Funding

10

Number of Employees

$2M

Revenue (est)

-9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.9M100%$3M
#2
$0.8M10-17%N/A
#3
$0.9M10-33%N/A
#4
$1.7M1011%N/A
#5
$1.1M10-9%N/A